// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Healthcare costs associated with short-acting ß2-agonist use in asthma: an observational UK study from the SABINA global programme

Darush Attar - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort

Ayesha Kumar - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Azithromycin

A preliminary study to identify correlations between blood glucose levels and cardiorespiratory observations in acute asthma patients receiving nebulised salbutamol

Craig Mortimer - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Hydrocortisone

The effects of nebulised beta-2 agonists on clinical observations in asthma exacerbations: a systematic review

Craig Mortimer - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Shared decision making in severe asthma therapy: qualitative study of physician-patient communication

Ember Lu - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Response to mepolizumab in patients with severe CRSwNP using EUFOREA 2021 criteria

Claire Hopkins - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Mepolizumab

International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A

Charles Pilette - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

CAPTAIN: Improvements in airflow obstruction in patients with uncontrolled asthma

Dave Singh - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Advair HFA

CAPTAIN: Relationship between FEV1 reversibility at screening as a continuous variable and treatment response

Guy Brusselle - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Umeclidinium

CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA

Huib A.M. Kerstjens - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Umeclidinium

Mometasone/indacaterol demonstrates similar efficacy in men and women: pooled analyses of PALLADIUM and IRIDIUM studies

Christian Gessner - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study

Chantal Raherison-Semjen - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Seebri Breezhaler

Lung deposition and distribution of inhaled extra fine beclomethasone dipropionate / formoterol fumarate /glycopyrronium bromide (BDP/FF/GB) in subjects with and without airflow obstruction

Simonetta Baldi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Beclomethasone dipropionate

SABA use increase weeks before asthma exacerbations recorded via a digital inhaler

Mark Levy - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Salbutamol

The sustainability agenda and inhaled therapy: what do patients want?

Grainne D'Ancona - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Change from MDI to DPI in asthma: effects on climate emissions and disease control

Ashley Woodcock - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Fluticasone furoate

Characteristics and treatment pathways of patients with COPD receiving a long-acting muscarinic antagonist/long-acting ß2-agonist (LABA/LAMA) in the UK

Gema Requena - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK

Alexandrosz Czira - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

The effect of fluconazole on the pharmacokinetics of ensifentrine in healthy individuals

Tara Rheault - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fluconazole

Sugar coating hypoxia – Metformin risks?

David Barber - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Metformin Hydrochloride

Copyright © 2026. QuantiNova All rights reserved